{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:29:02Z","timestamp":1777656542271,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro (AIRC Milano)"},{"name":"Special Program Molecular Clinical Oncology 5\u00d71000"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.leukres.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T15:26:14Z","timestamp":1379604374000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper"],"prefix":"10.1016","volume":"38","author":[{"given":"Giovanni","family":"Barosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.leukres.2013.09.008_bib0005","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2013.09.008_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0015","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2008"},{"issue":"23","key":"10.1016\/j.leukres.2013.09.008_bib0020","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) Consensus Report","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0030","series-title":"Group techniques for program planning: a guide to nominal group and Delphi processes","author":"Delbecq","year":"1975"},{"issue":"1","key":"10.1016\/j.leukres.2013.09.008_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation-2010.1.129","article-title":"Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera","volume":"2010","author":"Harrison","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2013.09.008_bib0050","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"44","article-title":"Primary myelofibrosis","author":"Thiele","year":"2008"},{"issue":"1","key":"10.1016\/j.leukres.2013.09.008_bib0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.008_bib0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Buhr","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.008_bib0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1309\/AJCP2UG9SGGWAHUA","article-title":"Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia","volume":"136","author":"Koopmans","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.008_bib0070","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","article-title":"Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis","volume":"56","author":"Brousseau","year":"2010","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.008_bib0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.061432","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Thiele","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.leukres.2013.09.008_bib0080","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0016-5085(82)80131-5","article-title":"Observer variation in assessment of jejunal biopsy specimens. A comparison between subjective criteria and morphometric measurement","volume":"83","author":"Corazza","year":"1982","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/path.1711770212","article-title":"A megakaryocyte analysis of the bone marrow in patients with myelodysplastic syndrome, myeloproliferative disorder and allied disorders","volume":"177","author":"Ohshima","year":"1995","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.008_bib0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.leukres.2013.09.008_bib0100","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2","article-title":"An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression","volume":"68","author":"Barosi","year":"1991","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2013.09.008_bib0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd\u2013Chiari syndrome or portal vein thrombosis","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.008_bib0110","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.leukres.2013.09.008_bib0115","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2013.09.008_bib0120","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.008_bib0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.leukres.2013.09.008_bib0130","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.008_bib0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2013.09.008_bib0140","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"9501","key":"10.1016\/j.leukres.2013.09.008_bib0145","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.leukres.2013.09.008_bib0155","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2013.09.008_bib0160","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.008_bib0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.leukres.2013.09.008_bib0170","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.008_bib0180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.09.008_bib0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.leukres.2013.09.008_bib0190","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.008_bib0195","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"Nov","key":"10.1016\/j.leukres.2013.09.008_bib0200","first-page":"801","article-title":"Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF)","volume":"120","author":"Cervantes","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7650","key":"10.1016\/j.leukres.2013.09.008_bib0205","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2013.09.008_bib0210","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.leukres.2013.09.008_bib0215","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd\u2013Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0220","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.008_bib0225","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","article-title":"Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea","volume":"41","author":"L\u00f6fvenberg","year":"1988","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.008_bib0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","article-title":"Melphalan treatment in patients with myelofibrosis with myeloid metaplasia","volume":"116","author":"Petti","year":"2002","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.leukres.2013.09.008_bib0235","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2013.09.008_bib0245","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.008_bib0250","first-page":"200","article-title":"Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction","volume":"7","author":"Barosi","year":"1993","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2013.09.008_bib0255","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.008_bib0260","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","author":"Santos","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T10:00:06Z","timestamp":1596535206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613003251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0145212613003251"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}